CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies
Open Access
- 31 July 2024
- journal article
- Published by Elsevier in Blood Neoplasia
- Vol. 1 (4) , 100032
Abstract
No abstract availableKeywords
Funding Information
- CancerFree KIDS (810753-1222-00)
- Research Institute, Nationwide Children's Hospital (AWD00001677, 45306-0015-1222)
This publication has 34 references indexed in Scilit:
- Isatuximab: A Review of Its Use in Multiple MyelomaTargeted Oncology, 2021
- CAR-T cell therapy: current limitations and potential strategiesBlood Cancer Journal, 2021
- Unraveling the mysteries of plasma cells2020
- Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myelomaBlood Cancer Journal, 2019
- Off-the-Shelf CAR-NK Cells for Cancer ImmunotherapyCell Stem Cell, 2018
- Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphomaAmerican Journal of Hematology, 2017
- Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL212016
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumabLeukemia, 2015
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AMLNature Biotechnology, 2010